SAN DIEGO–(BUSINESS WIRE)—- $ARCT #65Roses–Arcturus Therapeutics Holdings Inc. (“Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to help support the Phase 3 development and potential commercialization of ARCT-032, Arcturus’ investigational mRNA therapy for Cystic Fibrosis. The collaboration will leverage Thermo
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
